youtube_live
Q3 2026: ieņēmumi • pēc 4 dienām
Skatīt detalizētu informācijuchevron_right
NVO:NYSE
Novo Nordisk A/S
40,00 $
arrow_upward
+2,17%(+0,85) 1 d.
39,97 $
arrow_downward
-0,07% (-0,030)bedtimePēctirdzniecības
Slēgts: 30. okt., 16:00:05 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
39,61 $
Augsta
40,10 $
Zema
39,54 $
Tirgus kapitalizācija
134,62 mljrd.
Vid. apjoms
13,22 milj.
Apjoms
15,28 milj.
Dividende
4,49%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,21
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,92 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
39,61 $
Augsta
40,10 $
Zema
39,54 $
Tirgus kapitalizācija
134,62 mljrd.
Vid. apjoms
13,22 milj.
Apjoms
15,28 milj.
Dividende
4,49%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,21
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
3,92 $
Beta
0,75
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Yahoo Finance
·
pirms 3 stundām
Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings?
Zacks
·
pirms 16 stundām
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Traders Union
·
pirms 17 stundām
What's behind Novo Nordisk's latest stock surge?
Zacks
·
pirms 19 stundām
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Profils
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com